Statement re Proposed Return

Evolutec Group PLC
05 June 2007

Tuesday 5 June 2007



                               Evolutec Group plc
                         ('Evolutec' or 'the Company')

                    Proposed return of cash to shareholders

The Board of Evolutec announces that, having completed a thorough strategic
review of its options including consideration of a number of conditional
proposals for the reverse take-over or merger of the Company, and following
consultation with its major institutional shareholders, it intends to recommend
the return of all remaining cash to shareholders (after full settlement of all
liabilities). This will be effected by placing the Company into members'
voluntary liquidation. The Company is also proposing to delist its shares from
the Alternative Investment Market of the London Stock Exchange with effect from
9 July 2007.

The members' voluntary liquidation and delisting of the Company's shares will be
subject to shareholder approval. Accordingly, the Board intends to send a
circular to shareholders convening an extraordinary general meeting to be held
on Friday, 6 July 2007 to consider the relevant resolutions.

It is expected that the members' voluntary liquidation will be conducted by
Samantha Keen and Trevor O'Sullivan each of Grant Thornton UK LLP ('Joint
Liquidators'). The Joint Liquidators will be responsible for agreeing creditors'
claims and thereafter distributing surplus cash to shareholders.

The Board of Evolutec has discussed the amount and timing of distribution to
shareholders with the Joint Liquidators. On the basis of such discussions, the
Board expects that a total amount of approximately £5.5 million will be
available for distribution to shareholders representing approximately 21.3 pence
per ordinary share. Whilst the exact amount and timing of any distribution is
uncertain, the Joint Liquidators have indicated that a first distribution of
approximately 60% of the expected distribution should be paid to shareholders in
October 2007. A second distribution will be made in 2008 subject to tax
clearances.

Mark Carnegie Brown, Chief Executive of Evolutec, said:

'The disappointing clinical results with rEV131 earlier this year made it
difficult to continue in the public market. While this outcome is a
disappointment to the Board and shareholders it remains the best solution given
the company's market capitalisation and the time to value for its remaining
programmes.'



Enquiries:

Evolutec                                                         0118 922 4480
Mark Carnegie Brown, Chief Executive Officer
Nicholas Badman, Chief Financial Officer

Numis Securities Limited                                         020 7260 1500
Michael Meade

Financial Dynamics                                               020 7831 3113
David Yates
Ben Brewerton




                      This information is provided by RNS
            The company news service from the London Stock Exchange